Andreas Rummel Selected Research

Botulinum Toxins (Botulinum Toxin)

1/2022	Construction and validation of safe Clostridium botulinum Group II surrogate strain producing inactive botulinum neurotoxin type E toxoid.
1/2019	Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology.
6/2018	The hypothetical protein P47 of Clostridium botulinum E1 strain Beluga has a structural topology similar to bactericidal/permeability-increasing protein.
1/2018	Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
8/2017	Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission.
1/2017	Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H.
1/2017	Two Feet on the Membrane: Uptake of Clostridial Neurotoxins.
1/2017	A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.
9/2016	Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry.
1/2016	Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Rummel Research Topics

Disease

17	Botulism 01/2022 - 12/2006
14	Paralysis (Palsy) 01/2018 - 07/2004
3	Tetanus 12/2013 - 02/2004
2	Respiratory Insufficiency (Respiratory Failure) 01/2017 - 01/2016
2	Muscle Spasticity (Spastic) 01/2017 - 09/2009
1	Foodborne Diseases 01/2021
1	Diarrhea 01/2021
1	Dystonia (Limb Dystonia) 08/2017
1	Muscular Diseases (Myopathy) 01/2017
1	Paresis (Hemiparesis) 01/2017
1	Autonomic Nervous System Diseases (Dysautonomia) 01/2017
1	Sialorrhea 01/2017
1	Hyperhidrosis 01/2017
1	Constipation 12/2015
1	Pseudomembranous Enterocolitis (Pseudomembranous Colitis) 02/2015
1	Nervous System Diseases (Neurological Disorders) 12/2011

Drug/Important Bio-Agent (IBA)

24	Botulinum Toxins (Botulinum Toxin)IBA 01/2022 - 02/2004
6	incobotulinumtoxinA FDA Link 01/2017 - 09/2009
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2017 - 09/2009
3	tetanospasmin (tentoxilysin)IBA 01/2017 - 06/2009
3	Cholinergic Agents (Cholinergics)IBA 01/2017 - 07/2004
2	SNARE Proteins (SNAREs)IBA 01/2018 - 08/2017
2	Proteins (Proteins, Gene)FDA Link 04/2014 - 12/2011
2	NeurotoxinsIBA 04/2014 - 12/2013
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Clostridium enterotoxinIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2018
1	Qa-SNARE Proteins (Syntaxin)IBA 08/2017
1	CosmeticsIBA 01/2017
1	AntitoxinsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2016
1	Galactose (Galactopyranose)FDA LinkGeneric 12/2015
1	Lactulose (Duphalac)FDA LinkGeneric 12/2015
1	SugarsIBA 12/2015
1	Virulence Factors (Pathogenicity Factors)IBA 02/2015
1	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 04/2014
1	Neutralizing AntibodiesIBA 12/2011
1	Neurotransmitter Agents (Neurotransmitter)IBA 09/2009
1	GangliosidesIBA 02/2004

Therapy/Procedure

1	Therapeutics 08/2017
1	Critical Care (Surgical Intensive Care) 01/2017